Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Solara Active Pharma Sciences's enterprise value is ₹34,058 Mil.
Solara Active Pharma Sciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹1,937 Mil. Therefore, Solara Active Pharma Sciences's EV-to-EBITDA for today is 17.58.
The historical rank and industry rank for Solara Active Pharma Sciences's EV-to-EBITDA or its related term are showing as below:
NSE:SOLARAPP1'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -81.75 Med: 12.14 Max: 142.84
Current: 21.94
During the past 10 years, the highest EV-to-EBITDA of Solara Active Pharma Sciences was 142.84. The lowest was -81.75. And the median was 12.14.
NSE:SOLARAPP1's EV-to-EBITDA is ranked worse than 73.29% of 745
companies
in the Drug Manufacturers industry
Industry Median: 12.56
vs NSE:SOLARAPP1: 21.94
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Solara Active Pharma Sciences (NSE:SOLARAPP1) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Solara Active Pharma Sciences's PE Ratio (TTM) for today is calculated as:
Solara Active Pharma Sciences's share price for today is ₹267.45.
Solara Active Pharma Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-0.620.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Solara Active Pharma Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solara Active Pharma Sciences EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Solara Active Pharma Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Solara Active Pharma Sciences's EV-to-EBITDA falls into.
Solara Active Pharma Sciences's current Enterprise Value is ₹34,058 Mil.
Solara Active Pharma Sciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,937 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solara Active Pharma Sciences (NSE:SOLARAPP1) has a EV-to-EBITDA of 17.58 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Solara Active Pharma Sciences. This is 45% above median its historical median of 12.14. According to the industry distribution chart, Solara Active Pharma Sciences ranks #546 out of 745 companies in the Drug Manufacturers industry, placing it in the top 73.3%.
Is Solara Active Pharma Sciences' EV-to-EBITDA too high?
Solara Active Pharma Sciences' current EV-to-EBITDA of 17.58 is 45% above median its 10-year median of 12.14. The Drug Manufacturers industry median EV-to-EBITDA is 12.56. Solara Active Pharma Sciences' value of 17.58 is 40% above this industry median. Based on the distribution chart, Solara Active Pharma Sciences ranks #546 out of 745 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Solara Active Pharma Sciences has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Solara Active Pharma Sciences' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Solara Active Pharma Sciences ranks #546 out of 745 companies for EV-to-EBITDA. This places Solara Active Pharma Sciences in the lower half of its industry. The industry median EV-to-EBITDA is 12.56. Solara Active Pharma Sciences' value of 17.58 is 40% above this benchmark. While the company's 10-year median is 12.14 vs. the industry median of 12.56, Solara Active Pharma Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.56, based on 745 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Solara Active Pharma Sciences's current EV-to-EBITDA of 17.58 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Solara Active Pharma Sciences. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solara Active Pharma Sciences's current EV-to-EBITDA is 17.58, which is 45% above median its own 10-year median of 12.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solara Active Pharma Sciences stock overvalued right now?
Solara Active Pharma Sciences (NSE:SOLARAPP1) has a current EV-to-EBITDA of 17.58. The stock's GF Value™ is ₹208.54, compared to a current price of ₹267.45 — trading 28.2% above its estimated fair value. The current EV-to-EBITDA is 17.58, which is 45% above median its 10-year median of 12.14 and 40% above the Drug Manufacturers industry median of 12.56. Solara Active Pharma Sciences' overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Solara Active Pharma Sciences (NSE:SOLARAPP1), the current EV-to-EBITDA is 17.58 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Solara Active Pharma Sciences (NSE:SOLARAPP1) Overvalued in 2026?
Based on GuruFocus' analysis, Solara Active Pharma Sciences stock appears to be overvalued.
The current stock price of ₹267.45 is trading 28.2% above its estimated GF Value™ of ₹208.54.
Key valuation signals for NSE:SOLARAPP1:
EV-to-EBITDA: 17.58 (45% above median its 10-year median of 12.14)
GF Value™: ₹208.54 vs. price of ₹267.45 (28.2% above fair value)
Industry Position: 40% above the Drug Manufacturers median (#546 of 745)
No single metric tells the full story. See the NSE:SOLARAPP1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Solara Active Pharma Sciences Ltd is engaged in the Active Pharmaceutical Ingredients (API) in India. It manufactures and develops APIs and offers services, including CRAMS and contract manufacturing for APIs. The company offers products and services, such as Anaesthetic, Analgesics, Antiviral, Retinoid, Anti-emetic, Antimalarial, Diuretic, Muscle relaxant, Antiallergics, Antihypertensive, Calcimimetic agent, Anti-seizure, Antigout, Cardiovascular, Anti-infective, Cough suppressant, and others. It also offers contract services, including contract development and manufacturing, and analytical services. Geographically, the company generates all of its revenue from India.
64GF Score
Get the complete analysis for NSE:SOLARAPP1
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SOLARAPP1 has been successfully added to your 
